Nataliya Smith Selected Research

OKN 007

1/2022	OKN-007 Alters Protein Expression Profiles in High-Grade Gliomas: Mass Spectral Analysis of Blood Sera.
1/2022	A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
1/2021	Temporary opening of the blood-brain barrier with the nitrone compound OKN-007.
11/2020	OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma.
10/2019	Association of decreased levels of lipopolysaccharide-binding protein with OKN-007-induced regression of tumor growth in an F98 rat glioma model.
2/2019	OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth.
1/2019	Anti-inflammatory agent, OKN-007, reverses long-term neuroinflammatory responses in a rat encephalopathy model as assessed by multi-parametric MRI: implications for aging-associated neuroinflammation.
10/2015	OKN-007 decreases free radical levels in a preclinical F98 rat glioma model.
1/2015	Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.
1/2015	OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nataliya Smith Research Topics

Disease

25	Neoplasms (Cancer) 01/2022 - 01/2007
21	Glioma (Gliomas) 01/2022 - 09/2008
12	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2015
2	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2015
2	Carcinogenesis 01/2022 - 01/2021
2	Pain (Aches) 01/2021 - 03/2016
2	Neoplasm Metastasis (Metastasis) 09/2020 - 01/2020
2	Breast Neoplasms (Breast Cancer) 09/2020 - 12/2019
2	Interstitial Cystitis (Interstitial Cystitis, Chronic) 01/2020 - 06/2018
2	Brain Diseases (Brain Disorder) 01/2019 - 12/2013
2	Hypoxia (Hypoxemia) 03/2013 - 01/2013
1	Oligodendroglioma 01/2022
1	Medulloblastoma 01/2022
1	Multiple Sclerosis 04/2021
1	Inflammation (Inflammations) 04/2021
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 04/2021
1	Abdominal Pain (Pain, Abdominal) 01/2021
1	Diffuse Intrinsic Pontine Glioma 11/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2019
1	Neuroinflammatory Diseases 01/2019
1	Atrophy 01/2019
1	Sarcopenia 01/2019
1	Muscular Atrophy (Muscle Atrophy) 01/2019
1	Hypersensitivity (Allergy) 06/2018
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 06/2018
1	Cognitive Dysfunction 11/2015

Drug/Important Bio-Agent (IBA)

11	OKN 007IBA 01/2022 - 03/2013
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2013
7	Biomarkers (Surrogate Marker)IBA 04/2021 - 01/2013
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 01/2013
7	Free RadicalsIBA 01/2019 - 09/2008
6	Epidermal Growth Factor (EGF)IBA 04/2021 - 01/2013
6	alpha-latrotoxin receptorIBA 04/2021 - 01/2013
5	Contrast MediaIBA 09/2020 - 01/2007
5	Biotin (Vitamin H)FDA Link 10/2015 - 03/2010
4	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 07/2015
3	Caspase 3 (Caspase-3)IBA 01/2021 - 03/2013
3	AntibodiesIBA 01/2019 - 11/2007
3	GoldIBA 10/2015 - 03/2010
3	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2015 - 04/2011
3	LipidsIBA 01/2015 - 04/2012
2	Investigational DrugsIBA 01/2021 - 01/2019
2	Bevacizumab (Avastin)FDA Link 01/2020 - 07/2015
2	Immunoglobulin G (IgG)IBA 01/2019 - 09/2017
2	Malondialdehyde (Propanedial)IBA 10/2015 - 12/2013
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 10/2015 - 03/2010
2	3-nitrotyrosineIBA 10/2015 - 12/2013
2	Gadolinium DTPA (Magnevist)FDA Link 12/2013 - 01/2013
2	diethylenetriamineIBA 12/2013 - 01/2013
2	PENTAIBA 12/2013 - 01/2013
2	Acetic Acid (Vinegar)FDA LinkGeneric 12/2013 - 01/2013
2	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 03/2013 - 01/2013
2	Carbonic Anhydrase IXIBA 03/2013 - 01/2013
2	Protons (Proton)IBA 12/2011 - 09/2008
2	Molecular Probes (Molecular Probe)IBA 04/2011 - 02/2010
1	Peptides (Polypeptides)IBA 01/2022
1	ExoribonucleasesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 04/2021
1	Single-Chain AntibodiesIBA 01/2021
1	Biopolymers (Biopolymer)IBA 01/2021
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 11/2020
1	dipinacoline glutamateIBA 11/2020
1	activin AIBA 11/2020
1	LDN 193189IBA 11/2020
1	Histones (Histone)IBA 11/2020
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 09/2020
1	manganese ferriteIBA 09/2020
1	OvalbuminIBA 09/2020
1	Imiquimod (Aldara)FDA LinkGeneric 09/2020
1	Monoclonal AntibodiesIBA 03/2020
1	Immunoglobulin FragmentsIBA 03/2020
1	Claudin-2IBA 01/2020
1	LigandsIBA 01/2020
1	AntigensIBA 01/2020
1	graphene oxideIBA 12/2019
1	lipopolysaccharide-binding proteinIBA 10/2019
1	ImmunosorbentsIBA 10/2019
1	EnzymesIBA 10/2019
1	OxidesIBA 10/2019
1	Benzene (Benzole)IBA 10/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2019
1	Superoxides (Superoxide)IBA 01/2019
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2019
1	LipopolysaccharidesIBA 01/2019
1	Oxygen (Dioxygen)IBA 01/2019
1	Protamines (Protamine Sulfate)FDA Link 06/2018
1	Vasodilator Agents (Vasodilators)IBA 11/2015
1	albumin-(gadolinium-DTPA)IBA 10/2015
1	AntioxidantsIBA 10/2015
1	TransferasesIBA 07/2015

Therapy/Procedure

13	Therapeutics 01/2022 - 01/2015
3	Immunotherapy 09/2020 - 12/2011
3	Lasers (Laser) 09/2020 - 12/2011
3	Drug Therapy (Chemotherapy) 01/2020 - 07/2015
2	Intravenous Administration 01/2013 - 01/2007
1	Photothermal Therapy 09/2020
1	Radiotherapy 01/2020
1	Precision Medicine 01/2020